Chemoproteomics Global Market Report 2026

The chemoproteomics market size has grown rapidly in recent years. It will grow from $1.77 billion in 2025 to $2.01 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increasing investment in proteomics research, growing pharmaceutical R&D activities, adoption of advanced mass spectrometry techniques, rising drug discovery and biomarker identification efforts, expansion of academic and research institutes.

The chemoproteomics market size is expected to see rapid growth in the next few years. It will grow to $3.36 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to growing integration of AI in proteomics analysis, increasing demand for high-throughput chemoproteomics platforms, rising focus on personalized medicine, expansion of contract research organizations, increasing adoption of multi-omics approaches. Major trends in the forecast period include increasing adoption of activity-based protein profiling, rising demand for quantitative proteomics techniques, growing integration of structural proteomics approaches, expansion of affinity-based protein profiling applications, rising focus on label-free and isotope labeling techniques.

The rising demand for personalized medicine is projected to accelerate the growth of the chemoproteomics market in the foreseeable future. Personalized medicine involves medical treatments and therapies customized for individual patients based on their genetic composition, biomarkers, and unique disease characteristics. The demand for personalized medicine is expanding due to progress in genomic technologies and molecular diagnostics, which enable physicians to design treatments tailored to a patient’s genetic profile and enhance therapeutic effectiveness. Chemoproteomics supports personalized medicine by detecting patient-specific protein-drug interactions and biomarker patterns, facilitating targeted therapies that optimize efficacy while reducing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration authorized 16 new personalized therapies for rare disease patients in 2023, compared to six in 2022, including seven oncology drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is propelling the growth of the chemoproteomics market.

Key companies operating in the chemoproteomics market are focusing on developing innovative solutions such as live cell target engagement platforms to accelerate drug discovery and improve early stage efficacy prediction. A live cell target engagement platform is a technology that measures how drug candidates interact with their molecular targets inside living cells in real time, providing more accurate and physiologically relevant data than traditional in vitro assays. For example, in September 2025, LeadArt Biotechnologies Inc., a US-based biotechnology research company, launched its INTRAP platform, a next-generation live-cell target engagement and chemoproteomics system, at AHeDD 2025. The platform integrates chemoproteomics, automation, and AI to analyze drug-target interactions directly within living cells. This enables researchers to identify and optimize drug candidates more efficiently, particularly for challenging or “undruggable” targets. By providing real-time, physiologically relevant data, INTRAP aims to improve early-stage success rates and accelerate the overall drug discovery process.

In March 2025, Momentum Biotechnologies, a US-based biotechnology company, acquired OmicScouts for an undisclosed amount. Through this transaction, Momentum Biotechnologies intends to strengthen its technological expertise in multi-omics data analytics and speed up its drug discovery and development processes. OmicScouts GmbH is a Germany-based biotechnology company that focuses on delivering comprehensive chemoproteomics services for drug discovery, with an emphasis on target identification, selectivity profiling, and mechanism-of-action research.

Major companies operating in the chemoproteomics market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Agilent Technologies Inc., Shimadzu Corporation, PerkinElmer Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Evotec SE, Promega Corporation, Cell Signaling Technology Inc., Seer Inc., ChomiX Biotech Inc., Abcam plc, Creative Proteomics Inc., MtoZ Biolabs Inc., Allumiqs Corporation, Dalriada Drug Discovery Ltd., MS Bioworks LLC.

North America was the largest region in the chemoproteomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemoproteomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemoproteomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemoproteomics market consists of revenues earned by entities by providing services such as target identification and validation, protein-ligand interaction profiling, activity-based protein profiling, biomarker discovery and validation, and quantitative proteomics and chemoproteomic data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemoproteomics market also includes sales of mass spectrometry instruments, liquid chromatography systems, bioinformatics and data analysis software, consumables and reagents, and automated sample preparation hardware. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chemoproteomics is a field within proteomics that employs chemical probes to systematically investigate protein interactions, functions, and modifications in complex biological systems. It facilitates the identification of drug targets, protein-ligand interactions, and the mapping of reactive sites across the proteome.

The primary technologies of chemoproteomics include activity-based protein profiling, quantitative proteomics, structural proteomics, affinity-based protein profiling, and label-free and isotope labeling techniques. Activity-based protein profiling (ABPP) uses chemical probes to selectively label and measure the functional activity of enzymes in complex biological samples. Product types include reagents and kits, instruments, software, and services. Applications include drug discovery, target identification and validation, biomarker discovery, proteome profiling, and other uses, while end users include pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and other end-users.

Tariffs on imported reagents, laboratory instruments, and analytical software are impacting the chemoproteomics market by increasing costs for instrument-intensive techniques and consumables, particularly affecting segments such as activity-based protein profiling and structural proteomics. Regions such as North America, Europe, and Asia-Pacific that rely heavily on imported high-end mass spectrometry instruments and reagents are most affected. While tariffs raise costs, they also encourage local manufacturing, development of domestic analytical platforms, and innovation in cost-efficient, high-throughput proteomics solutions, providing strategic opportunities for regional market players.

The chemoproteomics market research report is one of a series of new reports that provides chemoproteomics market statistics, including chemoproteomics industry global market size, regional shares, competitors with a chemoproteomics market share, detailed chemoproteomics market segments, market trends and opportunities, and any further data you may need to thrive in the chemoproteomics industry. This chemoproteomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.